Yuqin Song

6PUBLICATIONS
84CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 01, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

|Jan 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness Analysis.

Jing Yang, Qiu-Zi Zhong, Li-Ting Qian

|Oct 24, 2025
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.

Dejan Juric, Daniel Anderson, Afshin Dowlati

|Feb 28, 2025
Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial.

Yanyan Liu, Ningjing Lin, Shuhua Yi

|Jan 08, 2024
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.

Yuqin Song, Zhengming Jin, Zhi-Ming Li

|Feb 03, 2023
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.

Tingyu Wang, Xiuhua Sun, Lihua Qiu

Pageof 1

Frequent Collaborators

2 joint publications

Hui Zhou

2 joint publications

Zhen Cai

2 joint publications

Jun Zhu

2 joint publications

Dengju Li